STOCK TITAN
The best stock market news and trading tools all in one place—your must-have platform for investing success.
A must-have platform for stock market information, offering the best tools and updates to supercharge your trading.
Your trusted source for the best stock market news, trading tools, and expert advice. Everything traders need, in one place.

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
TScan Therapeutics, Inc. (TCRX) will present at the 23rd Annual Needham Virtual Healthcare Conference to discuss their TCR-engineered T cell therapies for cancer treatment. The presentation will be available via webcast on their website.
Positive
  • None.
Negative
  • None.

WALTHAM, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 2:15 p.m. Eastern Time.

A webcast of the presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing TCR-T candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex therapeutic TCR-Ts for patients with a variety of cancers.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Melissa Forst
Argot Partners
212-600-1902
TScan@argotpartners.com


FAQ

When will TScan Therapeutics present at the 23rd Annual Needham Virtual Healthcare Conference?

TScan Therapeutics will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 2:15 p.m. Eastern Time.

What is the focus of TScan Therapeutics' development?

TScan Therapeutics is focused on the development of TCR-engineered T cell therapies (TCR-T) for cancer treatment.

Where can I watch the presentation by TScan Therapeutics?

The presentation by TScan Therapeutics will be available via webcast on the 'Events and Presentations' section of the Company's website at ir.tscan.com.

TScan Therapeutics, Inc.

NASDAQ:TCRX

TCRX Rankings

TCRX Latest News

TCRX Stock Data

242.57M
52.81M
0.82%
93.37%
4.09%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WALTHAM